Therapeutics News and Research

RSS

Scientists weaponize an antibody to deliver continuous attacks on cancer cells

In a recent study published in Molecular Cancer Therapeutics, researchers at the Weizmann Institute of Science paired the active ingredient of a garden remedy with advanced bio-technology to deliver a powerful punch against cancer. The cancer killing effectiveness lies in their technique of arming a cancer-targeting antibody with the destructive potential of the dietary molecule otherwise known as "allicin."

22 Apr 2005

New strategy to identify differences between non-metastatic and highly metastatic breast cancer cells

Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.

22 Apr 2005

Genes influence how heart failure patients respond to drugs

Genes dictate the color of our hair and eyes. They factor into whether we get cancer or heart disease. And, scientists increasingly recognize, they also ensure some patients will benefit from a prescription drug, while others develop adverse reactions or simply fail to respond at all.

21 Apr 2005

Fast Track designation for Terlipressin in type 1 hepatorenal syndrome

Protein Design Labs, Inc. and privately held Orphan Therapeutics, LLC today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).

20 Apr 2005

Halozyme Therapeutics receives FDA clearance for Cumulase

Halozyme Therapeutics has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Cumulase for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The active pharmaceutical ingredient in Cumulase is the first and only recombinant human hyaluronidase approved in the United States for cumulus removal in the IVF process.

20 Apr 2005

Compound derived from cottonseed oil could help improve the effectiveness of chemotherapy at treating head and neck cancer

The findings, which will be presented Tuesday, April 19, at the American Association for Cancer Research annual meeting, could lead to a treatment that provides an effective option to surgically removing the cancer, helping patients preserve vital organs involved in speech and swallowing.

19 Apr 2005

Researcher grows new insulin-secreting beta cells from pancreatic tissue

JDRF-funded researchers in Canada and Massachusetts have stimulated the birth of new insulin-secreting beta cells by treating human islets with a mixture of two naturally occurring peptides: epidermal growth factor (EGF) and gastrin.

12 Apr 2005

Groundbreaking results for the potential treatment of Huntington's Disease

Sirna Therapeutics announced today that its collaborator at the University of Iowa, Dr. Beverly Davidson, published groundbreaking results for the potential treatment of Huntington's Disease (HD).

12 Apr 2005

Significant progress in pSivida BioSilicon drug delivery evaluation

Global nanotechnology company pSivida Limited has announced that its evaluation of selected compounds from an undisclosed top five global pharmaceutical company has progressed successfully.

11 Apr 2005

Genomics and proteomics to increase the efficiency of drug discovery and development

While the United Sates is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to deploy genomics and proteomics as vital tools in drug discovery and development.

5 Apr 2005

DNA repair kit announced by scientists

A study by scientists at Sangamo BioSciences, Inc. has demonstrated the use of the Company's zinc finger DNA-binding protein (ZFP) technology to achieve highly efficient, permanent correction of a disease-causing gene in primary human cells.

5 Apr 2005

EvoGenix expands capabilities through US acquisition

EvoGenix and Absalus own complementary technologies which, when combined, are capable of streamlining the identification of new antibody drug candidates and improving the development of safe and effective human therapeutic antibodies.

4 Apr 2005

Statins, other cholesterol-depleting agents, may disrupt hypertension from developing

Cholesterol-lowering agents, such as the widely-prescribed statin drugs, and cholesterol-blocking agents may prove to be “novel therapeutic agents to modify cellular calcium that contributes to the development of pulmonary hypertension,” according Hemal H. Patel who lead a multidisciplinary team of researchers at the University of California, San Diego (UCSD).

3 Apr 2005

Simvastatin linked to protection against endothelial dysfunction in diabetic rats

Almost two years ago, the diabetes arm of the Heart Protection Study, the largest-ever study using a cholesterol-lowering medication, found that diabetics who took a daily dose of the statin drug simvastatin over five years reduced the risk of a first nonlethal heart attack by 37 percent and risk of a first nonfatal or fatal stroke by 24 percent, regardless of their cholesterol or glucose levels.

3 Apr 2005

Garlic protects against severe chronic pulmonary hypertension

Small daily doses of allicin, the active metabolic in garlic, proved effective in preventing a severe form of pulmonary hypertension in rats

3 Apr 2005

REPLICor to disclose unique antiviral drug

REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.

30 Mar 2005

Vical Incorporated issued two Canadian patents

Vical Incorporated announced today the issuance of two Canadian patents on the company's core technology, which involves direct administration of polynucleotide genetic material such as DNA or RNA.

29 Mar 2005

Discovery of gene STAT6(B) may lead to new treatments for inflammatory diseases

In a paper featured in Proceedings of the National Academy of Science (PNAS), researchers from Boston University School of Dental Medicine report the discovery of a new gene, STAT6(B), that helps regulate production of the potentially deadly tumor necrosis factor alpha (TNF-alpha) cytokine.

28 Mar 2005

Process for disposal of dying neutrophils actively linked to neutrophil production

New research identifies a critical inhibitory step that is a key component of the feedback circuit regulating the balance between neutrophil production and destruction.

23 Mar 2005

Study suggests combination therapy could stop spread, halt growth of melanomas

Researchers at Penn State College of Medicine have identified the mechanism by which the most mutated gene in melanoma, called v599EB-Raf, aids melanoma tumor development demonstrating its importance as a therapeutic target.

22 Mar 2005